BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 24152621)

  • 1. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified?
    Sharma P; Arora S; Mukherjee A; Pal S; Sahni P; Garg P; Khadgawat R; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Jan; 39(1):37-43. PubMed ID: 24152621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.
    Naswa N; Sharma P; Kumar A; Soundararajan R; Kumar R; Malhotra A; Ammini AC; Bal C
    Clin Nucl Med; 2012 Mar; 37(3):245-51. PubMed ID: 22310250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.
    Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Wängler B; Uebleis C; Schmidt GP; Göke B; Bartenstein P; Hacker M
    J Nucl Med; 2012 Nov; 53(11):1686-92. PubMed ID: 22984220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.
    Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Beuschlein F; Wängler B; Uebleis C; Schmidt GP; Spitzweg C; Bartenstein P; Hacker M
    Radiology; 2014 Feb; 270(2):517-25. PubMed ID: 24056402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
    Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
    Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors.
    Sharma P; Arora S; Dhull VS; Naswa N; Kumar R; Ammini AC; Bal C
    Abdom Imaging; 2015 Feb; 40(2):299-309. PubMed ID: 25134801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
    Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
    Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J
    J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
    Ambrosini V; Campana D; Bodei L; Nanni C; Castellucci P; Allegri V; Montini GC; Tomassetti P; Paganelli G; Fanti S
    J Nucl Med; 2010 May; 51(5):669-73. PubMed ID: 20395323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
    Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
    Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma.
    Sharma P; Thakar A; Suman K C S; Dhull VS; Singh H; Naswa N; Reddy RM; Karunanithi S; Kumar R; Kumar R; Malhotra A; Bal C
    J Nucl Med; 2013 Jun; 54(6):841-7. PubMed ID: 23520216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes.
    Sharma P; Mukherjee A; Karunanithi S; Naswa N; Kumar R; Ammini AC; Bal C
    Clin Nucl Med; 2015 Jul; 40(7):e351-6. PubMed ID: 25783509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
    Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
    Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
    Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
    Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?
    Ambrosini V; Campana D; Nanni C; Cambioli S; Tomassetti P; Rubello D; Fanti S
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1278-83. PubMed ID: 22584487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings.
    Naswa N; Sharma P; Soundararajan R; Karunanithi S; Nazar AH; Kumar R; Malhotra A; Bal C
    Abdom Imaging; 2013 Jun; 38(3):552-60. PubMed ID: 22743840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic values of
    Kumar R; Vankadari K; Mittal BR; Bansal D; Trehan A; Sahu JK; Sankhyan N
    Eur Radiol; 2021 Jul; 31(7):4587-4594. PubMed ID: 33409780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.